CrossrefInfokarte
Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer
Cancer Innovation · 2022-08 · 1 (2) · 119-123
DOI: 10.1002/cai2.21 ↗Abstract
Kein Abstract verfügbar.
EUVIMED